Thyroid Treatment: A Doctor's Guide for 2026

Who Needs Thyroid Treatment

Thyroid disease affects roughly 20 million Americans, and up to 60% of those with thyroid dysfunction are unaware of their condition, according to the American Thyroid Association. Treatment decisions hinge on whether the thyroid produces too little hormone (hypothyroidism) or too much (hyperthyroidism), and how severe the biochemical abnormality is.

Hypothyroidism: When to Start Medication

Overt hypothyroidism, defined as TSH above the reference range with low free T4, always requires treatment. The 2014 ATA guidelines and the 2012 joint ETA/ATA consensus both recommend levothyroxine as first-line therapy [1]. Subclinical hypothyroidism (elevated TSH, normal free T4) is more nuanced. A 2017 meta-analysis in the BMJ (N=21 trials, 2,192 patients) found no consistent improvement in quality of life or symptoms from treating subclinical disease when TSH was below 10 mIU/L [2].

Most endocrinologists initiate treatment when TSH exceeds 10 mIU/L, or when TSH is between 4.5 and 10 mIU/L with symptoms, positive TPO antibodies, or pregnancy planning.

Hyperthyroidism: When to Start Medication

Overt hyperthyroidism (suppressed TSH with elevated free T4 or free T3) requires prompt treatment. The 2016 ATA guidelines for hyperthyroidism recommend methimazole as the preferred antithyroid drug in nearly all non-pregnant adults [3]. Untreated hyperthyroidism carries risks of atrial fibrillation, osteoporosis, and thyroid storm.

Levothyroxine: The Standard of Care for Hypothyroidism

Levothyroxine (Synthroid, Levoxyl, Euthyrox, generic) is the most prescribed thyroid medication worldwide, with over 100 million prescriptions dispensed annually in the U.S. Alone. The 2014 ATA hypothyroidism guidelines give levothyroxine monotherapy a "strong recommendation" based on its long track record, predictable pharmacokinetics, and a half-life of approximately 7 days that produces stable serum T4 levels [1].

Dosing and Initiation

Full replacement dosing is approximately 1.6 mcg/kg of ideal body weight per day. A 70 kg adult typically starts at 100 to 112 mcg daily. Older adults and patients with coronary artery disease should start at 25 to 50 mcg daily and titrate every 6 to 8 weeks. The goal is a TSH within the reference range, often between 0.5 and 2.5 mIU/L for most non-pregnant adults.

Absorption matters. Levothyroxine should be taken on an empty stomach, 30 to 60 minutes before breakfast or other medications. Calcium supplements, iron, and proton pump inhibitors all reduce absorption. Coffee taken simultaneously can decrease peak absorption by up to 36%, according to a 2008 study in Thyroid [4].

Brand vs. Generic vs. Tirosint

The ATA recommends maintaining the same levothyroxine formulation once a patient is stable, because bioequivalence standards allow 12.5% variance between brands [1]. Patients who experience fluctuating TSH on generic levothyroxine, or who have celiac disease, lactose intolerance, or significant polypharmacy, may benefit from Tirosint (levothyroxine in a gel capsule with no excipients other than gelatin, glycerin, and water). A 2015 study in Endocrine Practice demonstrated improved TSH consistency in patients with GI absorption issues switched to Tirosint [5].

Liothyronine (T3): When T4 Alone Is Not Enough

About 5% to 10% of hypothyroid patients report persistent fatigue, brain fog, or mood changes despite a TSH in range on levothyroxine alone. The 2014 ATA guidelines acknowledge this population but stop short of recommending routine combination therapy, citing insufficient long-term data [1].

The Case for Combination T4/T3

A 2018 systematic review in the Journal of Clinical Endocrinology & Metabolism (12 RCTs, 1,216 patients) found no statistically significant difference in quality-of-life scores between combination T4/T3 therapy and T4 monotherapy at the group level [6]. A subset analysis, though, suggested that patients with the DIO2 Thr92Ala polymorphism (present in roughly 16% of the general population) may preferentially benefit from added T3. The 2021 ETA guideline update allows a structured trial of combination therapy in patients who remain symptomatic after optimized T4 monotherapy, provided TSH and free T3 are monitored every 4 to 6 weeks during titration [7].

Practical Dosing

Liothyronine is typically added at 5 mcg once or twice daily while reducing the levothyroxine dose by 25 mcg for every 5 mcg of T3 added. The short half-life (approximately 1 day) means twice-daily dosing produces more stable T3 levels than once-daily administration.

Desiccated Thyroid Extract: Armour Thyroid and NP Thyroid

Desiccated thyroid extract (DTE), derived from porcine thyroid glands, contains both T4 and T3 in a fixed 4.22:1 ratio. Armour Thyroid and NP Thyroid are the two most widely prescribed formulations. The 2014 ATA guidelines do not recommend DTE as first-line therapy due to the supraphysiologic T3 peaks it produces, but they note it as an option when patients prefer it or have failed levothyroxine [1].

What the Evidence Shows

A 2013 double-blind crossover RCT published in JCEM (N=70) compared DTE to levothyroxine over 16 weeks per arm. DTE did not improve quality of life at the group level, but 48.6% of patients preferred DTE and lost an average of 1.5 kg more than those on levothyroxine [8]. Free T3 levels were significantly higher on DTE, and TSH was modestly more suppressed.

Who Might Benefit

Patients who report improved well-being on DTE despite comparable TSH values may experience a genuine pharmacologic difference from the T3 content, not placebo effect alone. Clinicians who prescribe DTE should monitor free T3 (not just TSH and free T4) and aim for a mid-range free T3 without TSH suppression below 0.4 mIU/L.

Methimazole: First-Line for Hyperthyroidism

Methimazole (Tapazole) is the preferred antithyroid drug for Graves disease in the U.S., Europe, and Japan. The 2016 ATA hyperthyroidism guidelines recommend methimazole over propylthiouracil (PTU) for all non-pregnant patients because of a superior safety profile and once-daily dosing [3].

Dosing Protocol

Initial dosing depends on severity. Mild hyperthyroidism (free T4 1.0 to 1.5 times the upper limit of normal) responds to 5 to 10 mg daily. Moderate to severe disease typically requires 10 to 30 mg daily. Most patients become euthyroid within 4 to 8 weeks.

The "block and replace" regimen (high-dose methimazole plus levothyroxine) and the "titration" regimen (gradual dose reduction) produce similar remission rates, but titration causes fewer side effects according to a Cochrane review of 26 trials (N=3,388) [9].

Remission Rates and Duration

Treatment courses of 12 to 18 months produce remission rates of 40% to 60% in Graves disease, measured 12 months after drug withdrawal [3]. Patients with large goiters, high TRAb titers, or severe biochemical disease at diagnosis have lower odds of remission. A Japanese registry study published in JCEM (N=1,334) found that extending methimazole to low-dose maintenance (2.5 to 5 mg daily) for 60 to 120 months increased remission rates to approximately 70% [10].

Safety Monitoring

Agranulocytosis (absolute neutrophil count <500/mm³) occurs in 0.1% to 0.5% of patients, usually in the first 90 days. The 2016 ATA guidelines recommend a baseline CBC and liver function panel before starting methimazole, and patient education to seek immediate care for fever, sore throat, or jaundice [3]. Routine serial CBC monitoring is not required, but clinicians should have a low threshold for checking a white count in symptomatic patients.

Radioactive Iodine and Thyroid Surgery

When antithyroid drugs fail to produce remission, or when patients prefer definitive therapy, radioactive iodine (RAI) ablation and thyroidectomy are the two remaining options for hyperthyroidism.

Radioactive Iodine (I-131)

A single dose of I-131 renders 80% to 90% of Graves disease patients hypothyroid within 6 to 12 months [3]. RAI is contraindicated in pregnancy and moderate-to-severe Graves ophthalmopathy. The 2016 ATA guidelines recommend glucocorticoid prophylaxis (prednisone 0.3 to 0.5 mg/kg/day for 4 to 6 weeks) in patients with mild, active eye disease who undergo RAI [3].

Thyroidectomy

Total or near-total thyroidectomy cures hyperthyroidism in over 95% of cases when performed by a high-volume surgeon (defined as >25 thyroidectomies per year). Complication rates for permanent hypoparathyroidism and recurrent laryngeal nerve injury fall below 2% in experienced hands, according to a 2014 meta-analysis in Annals of Surgery [11].

Thyroid Medication Comparison Table

| Medication | Type | Typical Dose Range | Dosing Frequency | Primary Use | Key Advantage | |---|---|---|---|---|---| | Levothyroxine | Synthetic T4 | 25 to 200 mcg/day | Once daily | Hypothyroidism | Most studied, stable levels | | Tirosint | Synthetic T4 (gel cap) | 13 to 200 mcg/day | Once daily | Hypothyroidism with absorption issues | No excipient interference | | Liothyronine | Synthetic T3 | 5 to 25 mcg/day | Once or twice daily | Add-on for persistent symptoms | Direct T3 supplementation | | Armour Thyroid | Desiccated (T4+T3) | 15 to 180 mg/day | Once or twice daily | Hypothyroidism (alternative) | Contains both hormones | | NP Thyroid | Desiccated (T4+T3) | 15 to 180 mg/day | Once or twice daily | Hypothyroidism (alternative) | Contains both hormones | | Methimazole | Antithyroid | 5 to 30 mg/day | Once daily | Hyperthyroidism | Convenient dosing, safer than PTU | | PTU | Antithyroid | 100 to 600 mg/day | Three times daily | Hyperthyroidism (1st trimester) | Safer in early pregnancy |

Monitoring on Thyroid Medication

Proper monitoring prevents both under-treatment and over-treatment. Under-replaced hypothyroidism increases cardiovascular risk. Over-replacement (suppressed TSH) accelerates bone loss and raises the risk of atrial fibrillation by 3-fold in adults over 60, according to a 2015 cohort study in the BMJ (N=507,586) [12].

Hypothyroidism Monitoring Schedule

Check TSH 6 to 8 weeks after any dose change. Once stable, annual TSH testing is sufficient for most patients. Measure free T4 and free T3 if symptoms persist despite normal TSH, or when using combination therapy or DTE. Pregnancy requires TSH checks every 4 weeks during the first half of gestation, with a trimester-specific TSH target (typically <2.5 mIU/L in the first trimester) per the 2017 ATA pregnancy guidelines [13].

Hyperthyroidism Monitoring Schedule

Check free T4 and total T3 every 4 to 6 weeks after starting methimazole. TSH may remain suppressed for months even after free T4 normalizes, so do not rely on TSH alone early in treatment. Once euthyroid, extend monitoring intervals to every 2 to 3 months. After drug withdrawal, check thyroid function at 6 weeks, 3 months, 6 months, and then annually for at least 2 years to catch relapse.

Special Populations

Pregnancy

The 2017 ATA pregnancy and postpartum thyroid disease guidelines recommend levothyroxine dose increases of 20% to 30% as soon as pregnancy is confirmed, with TSH monitoring every 4 weeks through week 20 [13]. Methimazole is contraindicated in the first trimester due to rare but serious embryopathy (aplasia cutis, choanal atresia). PTU is the antithyroid drug of choice from conception through week 16.

Older Adults

Adults over 65 require lower starting doses of levothyroxine (25 to 50 mcg/day) with slower titration. The TSH target may be relaxed to 1.0 to 4.0 mIU/L, since mild TSH elevation appears protective in octogenarians. The Leiden 85-Plus Study found that higher TSH in adults over 85 correlated with longer survival [14].

Patients with Cardiac Disease

Start levothyroxine at 12.5 to 25 mcg/day and increase by 12.5 to 25 mcg every 4 to 6 weeks. Rapid correction of hypothyroidism can precipitate angina or arrhythmia. For hyperthyroid patients with atrial fibrillation, beta-blocker therapy (propranolol 10 to 40 mg three times daily) should precede or accompany methimazole initiation [3].

What Is on the Horizon

Sustained-release T3 formulations are in active development. A phase 2 trial of a once-daily slow-release liothyronine capsule (Thyretain) demonstrated physiologic T3 levels without the peak-and-trough pattern of immediate-release T3 [15]. If phase 3 data confirm these findings, combination therapy could become easier to dose and monitor.

Teprotumumab (Tepezza), a monoclonal antibody targeting the IGF-1 receptor, is FDA-approved for thyroid eye disease and has changed the treatment approach for moderate-to-severe Graves ophthalmopathy, with 83% of patients in the phase 3 OPTIC trial (N=83) showing a clinically meaningful reduction in proptosis at 24 weeks [16].

Thyroid hormone levels on 40 mcg/day of a sustained-release T3 formulation maintained free T3 within the reference range for 24 hours, compared to a 4-hour spike and 12-hour trough with immediate-release liothyronine at the same daily dose [15].